Want to see DE:EVK full AI Analyst Report?
Top Page
Evonik
(XETRA:EVK)
Select Model
Select Model
Rating:64Neutral
Price Target:
€19.50
▲(14.04% Upside)
Action:Reiterated
Date:08/07/26
Overall score reflects solid financial resilience led by strong cash flow and a generally sound balance sheet, plus supportive technical uptrend signals. These positives are held back by thin and volatile profitability and a high P/E multiple despite an attractive dividend yield.
Positive Factors
Strong cash generation
Consistent operating cash flow and a TTM free cash flow rebound (~+38%) provide durable internal funding for capex, dividends and R&D. Reliable cash conversion cushions the business through earnings volatility and supports strategic investments without heavy external financing.
Negative Factors
Thin and volatile profitability
Very slim net margins (TTM <1%) and prior net losses mean limited buffer against input-cost shocks. Thin bottom-line profitability constrains retained earnings, limits flexibility for sustained dividend increases, and makes long-term capital allocation more sensitive to cyclical swings.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent operating cash flow and a TTM free cash flow rebound (~+38%) provide durable internal funding for capex, dividends and R&D. Reliable cash conversion cushions the business through earnings volatility and supports strategic investments without heavy external financing.
Read all positive factors
Evonik (EVK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€8.17B
Dividend Yield5.7%
Average Volume (3M)1.24M
Price to Earnings (P/E)51.8
Beta (1Y)0.79
Revenue Growth-9.37%
EPS Growth-47.49%
CountryDE
Employees30,643
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.26
Shares Outstanding466,000,000
10 Day Avg. Volume1,023,876
30 Day Avg. Volume1,242,903
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)0.77
Price to Sales (P/S)0.44
P/FCF Ratio8.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.91Price Target Upside4.75% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)1.57
Revenue Forecast (FY)€14.51B
Evonik Business Overview & Revenue Model
Company Description
Evonik Industries AG operates primarily in the specialized chemicals market. Its business activities are structured across five principal divisions: Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & In...
How the Company Makes Money
Evonik primarily makes money by manufacturing and selling specialty chemical products and systems to industrial and consumer-facing customers, with revenue largely generated from (1) product sales under supply agreements and repeat purchasing rela...
Evonik Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
64
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.11B | 14.07B | 15.16B | 15.27B | 18.49B | 14.96B |
| Gross Profit | 3.13B | 3.24B | 3.74B | 3.39B | 4.23B | 4.03B |
| EBITDA | 2.11B | 1.84B | 1.76B | 991.00M | 2.07B | 2.18B |
| Net Income | 121.00M | 265.00M | 222.00M | -465.00M | 540.00M | 746.00M |
Balance Sheet | ||||||
| Total Assets | 18.61B | 19.21B | 19.75B | 21.26B | 21.81B | 22.28B |
| Cash, Cash Equivalents and Short-Term Investments | 390.00M | 619.00M | 618.00M | 1.03B | 1.12B | 919.00M |
| Total Debt | 4.46B | 3.87B | 3.78B | 4.25B | 4.22B | 3.64B |
| Total Liabilities | 10.68B | 11.04B | 10.65B | 12.28B | 10.75B | 12.91B |
| Stockholders Equity | 7.87B | 8.11B | 9.02B | 8.91B | 10.97B | 9.29B |
Cash Flow | ||||||
| Free Cash Flow | 846.00M | 695.00M | 873.00M | 801.00M | 785.00M | 929.00M |
| Operating Cash Flow | 1.63B | 1.44B | 1.71B | 1.59B | 1.65B | 1.81B |
| Investing Cash Flow | -558.00M | -652.00M | -663.00M | -653.00M | -777.00M | -1.07B |
| Financing Cash Flow | -1.06B | -731.00M | -1.33B | -823.00M | -672.00M | -856.00M |
Evonik Technical Analysis
Positive
17.10
Price Trends
16.37
Positive
16.10
Positive
14.56
Positive
Market Momentum
0.42
Negative
70.99
Negative
78.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EVK, the sentiment is Positive. The current price of 17.1 is below the 20-day moving average (MA) of 17.13, above the 50-day MA of 16.37, and above the 200-day MA of 14.56, indicating a bullish trend. The MACD of 0.42 indicates Negative momentum. The RSI at 70.99 is Negative, neither overbought nor oversold. The STOCH value of 78.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EVK.
Evonik Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | €8.17B | 51.80 | 1.89% | 5.85% | -9.37% | -47.49% | |
64 Neutral | €12.45B | 33.46 | 6.46% | 1.44% | -1.45% | -50.97% | |
63 Neutral | €8.83B | 38.70 | 5.27% | 3.22% | -9.48% | -56.88% | |
57 Neutral | €4.40B | -5.43 | -11.14% | 2.82% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | €1.43B | -2.16 | -17.77% | 0.65% | -14.31% | -386.04% | |
47 Neutral | €12.60B | -17.76 | -10.04% | ― | -8.72% | -140.66% |
* General Sector Average
DE:EVK
Evonik
18.05
2.18
13.71%
DE:BNR
Brenntag AG
64.64
10.91
20.31%
DE:1COV
Covestro
60.20
-0.36
-0.59%
DE:SY1
Symrise
91.82
13.14
16.70%
DE:LXS
LANXESS
17.18
-7.99
-31.75%
DE:WCH
Wacker Chemie AG
95.85
30.00
45.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.